KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Interest & Investment Income (2016)

CRISPR Therapeutics AG (CRSP) has disclosed Interest & Investment Income for 2 consecutive years, with $1000.0 as the latest value for Q4 2016.

  • Quarterly Interest & Investment Income rose 101.01% to $1000.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was -$8.0 million through Dec 2016, changed N/A year-over-year, with the annual reading at -$8.0 million for FY2016, 7353.7% down from the prior year.
  • Interest & Investment Income hit $1000.0 in Q4 2016 for CRISPR Therapeutics AG, up from -$1000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1000.0 in Q4 2016 to a low of -$8.0 million in Q1 2016.